[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100624748":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":32,"centralContacts":37,"locations":45,"responsibleParty":60,"collaborators":32,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":32,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":32,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":48,"whyStopped":32,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Centessa Pharmaceuticals (UK) Limited","INDUSTRY",[8,15,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A","EXPERIMENTAL","SAD Study in Healthy Adults: ORX489 and Placebo",[13,14],"Drug: ORX489 Tablets","Other: Placebo Tablets",{"label":16,"type":10,"description":17,"interventionNames":18},"Part B","Food-effect Evaluation in Healthy Adults: ORX489",[13],{"label":20,"type":10,"description":21,"interventionNames":22},"Part C","MAD Study in Healthy Adults: ORX489 and Placebo",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Part D","SAD Study in Acutely Sleep-Deprived Healthy Adults: ORX489 and Placebo",[13,14],[28,33],{"type":29,"name":30,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","ORX489 Tablets",[9,16,20,24],null,{"type":34,"name":35,"description":35,"armGroupLabels":36,"otherNames":32},"OTHER","Placebo Tablets",[9,20,24],[38,43],{"name":39,"role":40,"phone":41,"phoneExt":32,"email":42},"ORX489 Centessa Program Lead ORX489 Centessa Program Lead","CONTACT","617-468-5770","ORX489-101study@centessa.com",{"name":44,"role":40,"phone":32,"phoneExt":32,"email":32},"Celerion Program Lead CA49982 United States, Nebraska [Recruiting]",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":32},"Celerion","RECRUITING","Lincoln","Nebraska","68502","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-96.66696,40.8,{"lat":58,"lon":57},{"type":61,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100624748","phase-1-a-study-of-orx489-in-healthy-adult-participants-aged-18-to-60-years-100624748",false,"NCT07413666","A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years","A Safety, Tolerability, Pharmacokinetic, Food Effect, and Proof-of-Concept Study of Single and Multiple Doses of ORX489 in Healthy Adults","Inclusion Criteria:\n\n* Healthy males or females as determined by assessments at the Screening Visit.\n* For Parts A, B, C, and D: Participants must be at least 18 years of age and no more than 60 years of age at the Screening\n\nExclusion Criteria:\n\n* Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.\n* History of seizure disorder, any other condition that increases the risk of seizure\n* Has a clinically significant sleep disorder, including insomnia or sleep apnea",true,"ALL","18 Years","60 Years",{"count":74,"type":75},212,"ESTIMATED","INTERVENTIONAL",[78],"PHASE1","Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.",[81],"Healthy Adult Male and Female Volunteers",[83],"Healthy Volunteers orexin-2 receptor agonist","2026-02-23",{"date":86,"type":87},"2026-02-25","ACTUAL",{"date":86,"type":75},{"date":90,"type":75},"2027-06-30",{"name":5,"class":6},1]